News
Archives
- 2020
- Oct (1)
- Jul (1)
- Apr (1)
- 2019
- Dec (1)
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2018
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2017
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2016
- Oct (1)
- Apr (2)
- Jan (1)
- 2015
- 2014
- 2013
- Oct (1)
- Jul (1)
-
Apr (5)
- First investigator meeting for our new North Asia sites for the first time
- The National Cancer Institute (U.S) has recently labelled Aspirin in Colorectal Cancer as one of the most provocative questions in cancer
- We congratulate Dr Tham and team, and team from Sixth Affiliated Hospital
- Zhejiang and Zhongshan hospitals obtained IRB approval
- PIK3CA subgroup analysis included as a new secondary endpoint
- Jan (2)
- 2012
- Oct (2)
- Apr (1)
- Jan (1)
- 2011
- Oct (1)
- Jul (1)
- Apr (1)
30 Apr 2018
1st Quarter 2018

We have completed randomizing 23 subjects to replace subjects who did not fulfill critical eligibility criteria. Some sites received IRB confirmation to continue recruitment.
ASCOLT Data Monitoring Committee (DMC) has met on Jan 4 2018 and concluded with no concerns about toxicity related to treatment.